Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.

@article{Ericsson1996AngiographicAO,
  title={Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.},
  author={Christina Ericsson and Anders Hamsten and J. W. Nilsson and Lars Grip and Bertil Svane and Ulf H de Faire},
  journal={Lancet},
  year={1996},
  volume={347 9005},
  pages={849-53}
}
BACKGROUND Bezafibrate has effects on lipid metabolism and haemostatic function. We undertook a double-blind, placebo-controlled intervention trial, the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT), to establish whether bezafibrate (200 mg three times daily) could retard or prevent the progression of atherosclerotic lesions in dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event. METHODS 92 patients completed an… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 120 extracted citations

Similar Papers

Loading similar papers…